Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.70 |
| ▸ | NPY2R | P49146 | 8/20 | 0.69 |
| ▸ | NPY4R | P50391 | 8/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY1R | P25929 | 6/20 | 0.69 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.66 |
| ▸ | CALCR | P30988 | 6/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31656374 | 0.94 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29525147 | 0.92 | APLNR (0.63) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29526390 | 0.90 | APLNR (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29525492 | 0.89 | APLNR (0.64) | TFPI | |
| SCHEMBL29525577 | 0.89 | APLNR (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29526046 | 0.89 | APLNR (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| Sor-C13 SCHEMBL29926670 | 0.88 | TFPI (0.67) | TFPINPY2RNPY4RNPY5RNPY1R | |
| Buforin Ii SCHEMBL29357731 | 0.88 | NPY2R (0.71) | TFPINPY2RNPY4RNPY5RNPY1R | |
| Buforin Ii SCHEMBL29378594 | 0.88 | NPY2R (0.71) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29403150 | 0.87 | GHSR (0.66) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12311011-B2 | Des-acyl ghrelin and analogs as cancer therapies | CORNELL UNIVERSITY (US) | 2025-05-27 | — | — | US | claimed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-4081242-B1 | TREATMENT OF ACUTE HEART FAILURE | AnaCardio R&D AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12311011-B2 | Des-acyl ghrelin and analogs as cancer therapies | CORNELL UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| US-12311011-B2 | Des-acyl ghrelin and analogs as cancer therapies | CORNELL UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| US-12311011-B2 | Des-acyl ghrelin and analogs as cancer therapies | CORNELL UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240424001-A1 | LOCAL DELIVERY OF GROWTH AND REPAIR PROMOTING COMPOUNDS FOR TREATING, REDUCING AND/OR PREVENTING STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | STATERA PHARMA INC. (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4398875-A1 | LOCAL DELIVERY OF GROWTH AND REPAIR PROMOTING COMPOUNDS FOR TREATING, REDUCING AND/OR PREVENTING STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Statera Pharma Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4321525-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | Chengdu Sintanovo Biotechnology Co., Ltd (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20230346889-A9 | TREATMENT OF ACUTE HEART FAILURE | AnaCardio R&D AB (SE) | 2023-11-02 | — | — | US | disclosed |
| CN-113072617-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| WO-2023039500-A1 | LOCAL DELIVERY OF GROWTH AND REPAIR PROMOTING COMPOUNDS FOR TREATING, REDUCING AND/OR PREVENTING STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | STATERA PHARMA INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023028518-A2 | DOWNREGULATION OF CIRCULATING GHRELIN AND THERAPEUTIC APPLICATIONS THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4081242-A1 | TREATMENT OF ACUTE HEART FAILURE | ANACARDIO R&D AB (SE) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022206587-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | 成都诺和晟泰生物科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115052618-A | Treatment of acute heart failure | 抗核抗体卡迪奥研发公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220213076-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| US-11312709-B2 | Ghrelin O-acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | TFPI 4049/4885NPY2R 633/4885NPY4R 1081/4885 |
| US-20240158438-A1 | POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | GHSR, GHRHR, GIPR | TFPI 3562/4885NPY2R 32/4885NPY4R 38/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | TFPI 4049/4885NPY2R 633/4885NPY4R 1081/4885 |
| US-20220213076-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, GIPR, GPR119 | TFPI 1250/4885NPY2R 107/4885NPY4R 80/4885 |
| US-11312709-B2 | Ghrelin O-acyltransferase inhibitors | MBOAT4, GIPR, GPR119 | TFPI 1250/4885NPY2R 107/4885NPY4R 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.